Molecular structure of Trametinib, CAS Number: 871700-17-3
Trametinib (CAS 871700-17-3)
See product citations (19)
Alternate Names:
Trametinib is also known as GSK1120212.
Application:
Trametinib is an allosteric inhibitor of MEK1/MEK2 that reduces tumor growth in mouse xenograft models.
CAS Number:
871700-17-3
Purity:
≥98%
Molecular Weight:
615.39
Molecular Formula:
C26H23FIN5O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Trametinib is a molecule studied extensively in the context of molecular biology and oncology research due to its role as a mitogen-activated protein kinase (MEK) inhibitor. In laboratory applications, it is used to understand the signaling pathways involved in cell proliferation, differentiation, and survival. By inhibiting MEK, trametinib helps researchers to elucidate the MAPK/ERK pathway, which is often dysregulated in various forms of cancer. This has implications for understanding the molecular underpinnings of tumorigenesis and the development of resistance to cancer treatments. Additionally, trametinib is utilized in studies that investigate the combinatorial effects of targeting multiple pathways in cancer cells, examining the outcomes of using MEK inhibition alongside other methods. It also serves as a tool compound in cell signaling research to dissect the role of MEK in non-cancerous physiological processes.
Trametinib (CAS 871700-17-3) References
- Trametinib (GSK1120212) in the treatment of melanoma. | Salama, AK. and Kim, KB. 2013. Expert Opin Pharmacother. 14: 619-27. PMID: 23432625
- Trametinib: a MEK inhibitor for management of metastatic melanoma. | Lugowska, I., et al. 2015. Onco Targets Ther. 8: 2251-9. PMID: 26347206
- Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer. | Jeanson, A., et al. 2019. Expert Rev Anticancer Ther. 19: 11-17. PMID: 30513023
- Trametinib alleviates lipopolysaccharide-induced acute lung injury by inhibiting the MEK-ERK-Egr-1 pathway. | Chen, S., et al. 2020. Int Immunopharmacol. 80: 106152. PMID: 31926447
- Trametinib potentiates TRAIL-induced apoptosis via FBW7-dependent Mcl-1 degradation in colorectal cancer cells. | Lin, L., et al. 2020. J Cell Mol Med. 24: 6822-6832. PMID: 32352219
- Trametinib enhances ATRA-induced differentiation in AML cells. | Lu, H., et al. 2021. Leuk Lymphoma. 62: 3361-3372. PMID: 34355652
- Trametinib Inhibits the Growth and Aerobic Glycolysis of Glioma Cells by Targeting the PKM2/c-Myc Axis. | Gao, M., et al. 2021. Front Pharmacol. 12: 760055. PMID: 34744739
- Combinatorial effects of azacitidine and trametinib on NRAS-mutated melanoma. | Hanft, KM., et al. 2022. Pediatr Blood Cancer. 69: e29468. PMID: 34866327
- CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma. | Du, J., et al. 2022. Mol Cancer. 21: 18. PMID: 35039066
- Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib. | Vigoda, M., et al. 2022. Cancer Biol Ther. 23: 310-318. PMID: 35343367
- Targeting protein arginine methyltransferase 5 sensitizes glioblastoma to trametinib. | Banasavadi-Siddegowda, YK., et al. 2022. Neurooncol Adv. 4: vdac095. PMID: 35875691
- Predictive biomarkers for response to trametinib in non-small cell lung cancer. | Parekh, PR., et al. 2022. Tumour Biol. 44: 249-267. PMID: 36502357
- The MEK Inhibitor Trametinib Improves Outcomes following Subarachnoid Haemorrhage in Female Rats. | Bömers, JP., et al. 2022. Pharmaceuticals (Basel). 15: PMID: 36558896
Inhibitor of:
β-defensin 29, β-defensin 30, β-defensin 34, β-defensin 35, β-defensin 36, β-defensin 38, β-defensin 39, β-defensin 42, 1500010J02Rik, 1500032L24Rik, 1700008O03Rik, 1700012G19Rik, 1700020O03Rik, 1700090G07Rik, 2510049I19Rik, 2610030H06Rik, 2810426N06Rik, 2900053A13Rik, 4922501L14Rik, 4930558K02Rik, 5830482F20Rik, 9330159F19Rik, ACTR-I, AHNAK, AI987662, AIFL, apoL11a, ARMC10, ARMCX3, ASCC1, ASCL4, B230380D07Rik, B7-H3, BAGE5, BC034069, BC049349, BC055107, BC055324, BC057022, BC089597, Bcl-7b, BTNL10, Btnl6, Btnl7, BZW2, C030010C08Rik, C10orf122, C11orf49, C11orf71, C12orf59_D630042F21Rik, C130050O18Rik, C1orf149, C1orf159, C1orf161, C1orf190, C20orf160, C20orf59, C2orf29_D1Bwg0212e, C2orf30, C330005M16Rik, C330006A16Rik, C330006K01Rik, C330013F16Rik, C330019L16Rik, C35, C6orf106_D17Wsu92e, C6orf182_2410017P07Rik, C87414, C9orf140, Cables2, CASC1, CCDC7, Cid, claudin-3, CMTM1, CNK2, CNKSR3, COL20A1, CSAGE, CSN8, CT47C1, CXorf22, Cxx1b, Cypt2, Cypt4, DAN, dcTRAILR1, Dectin-2, DENND3, DEPDC1B, desmoglein 3, DIRC2, DNCLI2, DNLC2B, DNTNP, Dok-7, E2F-5, Ear10, ECRG4, EF-CAB3, EG229879, EG245651, EG330305, EG330513, EG330689, EG433365, EG434402, EG625464, EG626215, EG626456, ENX-1, EPR1, ERK 4, ERVMER34-1, F8A3, FAM131B, FAM131C, FAM149B1, FAM189B, FAM59B_Fam59b, FAM75C1, FBL22_Fbxl22, Fbxw21, FLJ11184, FLJ34931_BC027072, FLJ35220, FLJ39531, FLJ44815, FLJ46321, FOP, FSD1, GABP-α, GADD 45β, gankyrin, Gar22, GIPC, GITRL, GKLF, GM-CSFRα, Gm1027, Gm128, Gm3696, Gm9766, gp100, GRAMD1C, GSDMDC1, HACE1, Hairy Cell Leukemia Marker, HCCA2, HCNP, Headpin, HEB, HHCM, HNF-3β, HPK1, HSTF4, IFIT1, IGFL1, JTB, KIAA1549, KIAA1751, Klotho, KNDC1, KRBA1, KRBOX1, KRTAP25-1, LHX2, LIN-31, LNP1, LOC100039995, LOC100041238, LOC100041377, LOC100041416, LOC100041430, LOC100041448, LOC339047, LOC441617, LOC645478, LOC645851, LOC666187, LOC729303, LOC729521, LOC729942, LOC730198, LRRC61, LTH-A, Lung Carcinoma, Ly49F, Ly49I, LZTR1, MADD, MAGE-C3, MAMDC2, MAML3, MANBAL, MAP17, MAPKBP-1, MBIP, MEAF6, MEK kinase-1, MEK kinase-2, MEK kinase-4, MEK-1, MEK-2, MEK-4, MEK-5, MEK1, MEK2, MEKK 15, Mel-CAM, Melan-A, Melanoma Marker, MFRP, MGC26647, Mig12, MLTK, Mos, MS4A6A, MTLC, MXL-1, N-Shc, N-SMase2, NARF, NBPF7, NKAPL, NKG2-F, Nkx-6.1, Olfr1053, Olfr208, Olfr368, Olfr458, Olfr539, Olfr543, Olfr576, Olfr578, Olfr58, Olfr582, Olfr631, Olfr632, Olr1060, Olr1061, Olr1065, Olr1155, Olr1156, Olr1204, Olr1235, Olr125, Olr1259, Olr130, Olr1307, Olr1334, Olr1350, Olr1383, Olr1384, Olr1398, Olr1528, Olr1562, Olr1564, Olr157, Olr1630, Olr164, Olr1642, Olr1657, Olr1748, Olr223, Olr307, Olr322, Olr348, Olr357, Olr363, Olr374, Olr382, Olr410, Olr530, Olr653, Olr707, Olr726, Olr733, Olr749, Olr769, Olr772, Olr785, Olr791, Olr81, Olr836, Olr838, Olr879, Olr889, Olr943, Olr962, Olr964, OTTMUSG00000005148, OTTMUSG00000005215, OTTMUSG00000005288, OTTMUSG00000005304, OTTMUSG00000010673, OTTMUSG00000011275, PAGE-4, PATE-G, Pbx 2, PDCL2, Pelle, Pellino 2, Pet117, PFTAIRE-1, PHIP, PHTF2, PRAMEF21, preY, Prolifera, Proliferation Marker, PRR11, PTP22, Raf-B, Ras-GRF1, Ras-GRF2, RASAL1, RASGEF1A, RASGEF1B, RASL12, RASSF1, RASSF10, RASSF3, RASSF7, Reg Iα, RGC32, RGL1, RGPD4, RHAMM, RIM-BP3B, RIN1, RIT (Ras-like without CAAX), RP23-61E13.2, RPIB9, RREB1, Rsk-3, RSPRY1, SAP-1, SB144, SCO1, SCUBE3, Sdt, Sgo2, Shc, SKRP1, Smac, SNFT, Sp2, SPDYE2L, SPINK12, SPRED2, SS18L2, ST7L, STAP-2, STC2, Ste5, Ste7, SUSD2, syntenin-1, Tau-2, TDF, TESSP1, TFIIH p62, Thrombospondin 4, TMEFF1, TMEM212, Tmem217, Trav16dv11, Trav3n-2, Trav4d-3, Trefoil factor (TFF), TREM-2c, TSTD3, UBAP1L, USH3A, V1RC12, V1RC16, V1RC17, V1RD10, V1RD20, V1RD3, V1RE6, V1RE7, V1RE8, V1RI6, Vmn2r46, Vmn2r52, WFDC8, XAGE-1C, Xlr4, XPG, XXYLT1, ZNF264, ZNF726, ZNF732, and ZSCAN5B.Activator of:
3pK, 4E-T, ADAMTS, ADAMTS-18, ADAMTS-19, BJ-TSA-9, BXDC2, C030019I05Rik, C030039L03Rik, C7, C86695, Capicua, caspase-7, CD69, Cot, DDX56, DNA pol ε B, Dysadherin, EBP1, EG546272, EG546282, EG626215, EGFL3, ERBIN, EYA3, FAM128B, FANCI, FBXW18, FGF-5, GGTase-IIβ, gp130, HRPAP20, IL-17RA, IL-3Rβ, JNK1, Krs-2, KRTAP2, LRF, M-Ras, MAP-4, MEK-6, Melanoma, MFAP3L, MKP-7, MLLT11, MSK1, PCDHA9, PDGF-D, Rab 5B, raf-A, Raf-B, Ral GDS, RAO, RASAL3, Rif1, RSAD2, Sos 2, SPA-1, SPRED1, Sur-8, TIFAB, ULK4, and WDR82.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Trametinib, 5 mg | sc-364639 | 5 mg | $112.00 | |||
Trametinib, 10 mg | sc-364639A | 10 mg | $163.00 | |||
Trametinib, 1 g | sc-364639B | 1 g | $928.00 |